Cocrystal pharma reports second quarter 2025 financial results and provides updates on its antiviral drug-development programs

Bothell, wash., aug. 14, 2025 (globe newswire) -- cocrystal pharma, inc. (nasdaq: cocp) (“cocrystal” or the “company”) reports financial results for the three and six months ended june 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

COCP Ratings Summary

COCP Quant Ranking